New Lonza site can now make Covid-19 vaccine ingredient
Construction of an antibody production line at the new Lonza plant
Keystone / Olivier Maire
Swissmedic, the Swiss Agency for Therapeutic Products, has approved pharmaceutical company Lonza’s new site for making Moderna’s Covid-19 active substance.
This content was published on
1 minute
swissinfo.ch/sm
Español
es
Nuevo sitio de Lonza ya puede fabricar ingrediente de vacuna COVID-19
It issued the licence following a successful inspection of the production plant in Visp in southern Switzerland. At this newly approved site Lonza can manufacture, on behalf of Moderna, active substances for Covid-19 vaccines.
Swissmedic had already approved the first Swiss plant for the production of the substance in January 2021. At this newly approved site, called “Ibex® Solutions”, one production line is fully operational, and two more lines should be available soon.
Companies that manufacture or distribute medicinal or transplant products in Switzerland require an establishment licence proving that a company has the resources and processes needed to ensure and constantly monitor the quality of their products.
Lonza has a ten-year contract to supply ingredients to Moderna, including for up to one billion doses annually of Covid-19 vaccine.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss factory rushes to prepare for Moderna Covid-19 vaccine
This content was published on
Workers are racing to set up production lines at the Lonza factory in Visp to be able to start making a vaccine for US firm Moderna later this year.
This content was published on
The UN Human Rights Council approved the launch of this mechanism in Geneva on Friday, to be followed by an International Commission of Inquiry.
More than 100 wolves shot in Switzerland last year
This content was published on
Swiss hunters legally killed 101 wolves between February 1, 2024, and the end of January 2025. A further six died in accidents or from natural causes.
Swiss health office turns to Bluesky against backdrop of US censorship
This content was published on
The Swiss Federal Office of Public Health (FOPH) has joined the Bluesky social network, while US President Donald Trump works with X owner Elon Musk to censor content on official US websites.
Biotech company BioVersys is first Swiss IPO of 2025
This content was published on
The Basel-based biotech company BioVersys made the first initial public offering (IPO) of the year in Switzerland on Friday.
Much more spent on Swiss motorway vote campaigns than budgeted
This content was published on
Opponents and supporters of motorway expansion spent over CHF10 million ($11 million) on their campaigns, around a third more than announced in November.
Swiss researchers monitor animal populations with AI microphone
This content was published on
Researchers in Lausanne are using an intelligent microphone to make the animal world audible. The microphone automatically records animal sounds over large areas and analyses them using AI.
Three employees of Swiss aid organisation killed in DRC
This content was published on
Three employees of the Swiss Protestant Reformed Church (Heks) have been killed in an attack in the Democratic Republic of Congo (DRC). They were on a humanitarian mission in the crisis region.
This content was published on
All our waters today are pure at source," Muriel Lienau, general manager of Nestlé Waters, told AFP after press revelations.
Switzerland concerned about impact of US withdrawal from WHO
This content was published on
Switzerland has expressed concern about the loss of American experts and the freezing of contracts due to the announced withdrawal of the US from the World Health Organization (WHO).
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.